drugset / Trial / NCT03332095
Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the pharmacokinetics, safety, and tolerability of doravirine (also called MK-1439 or DOR) and doravirine/lamivudine/tenofovir disoproxil fumarate (also called MK-1439A or DOR/3TC/TDF) in HIV-1-infected children and adolescents.
Timeline
- Start
- 2018-07-02
- Primary completion
- 2020-08-19
- Completion
- 2022-05-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doravirine | Small molecule | 100 mg | Oral |
| Subject | Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate | Unknown | — | Oral |
| Background | Dolutegravir | Other / unclassified | — | — |
| Background | Raltegravir | Other / unclassified | — | — |